Status:
TERMINATED
A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
Lead Sponsor:
Pfizer
Conditions:
Triple Negative Breast Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This study is designed to evaluate the preliminary anti-tumor activity and tolerability of PF-03084014 when administered as a single agent in the treatment of patients with advanced triple receptor-ne...
Eligibility Criteria
Inclusion
- Histological or cytological diagnosis of triple negative breast cancer (TNBC) with evidence of a) metastatic or b) locally recurrent advanced disease that is not amenable to resection or radiotherapy with curative intent.
- Availability of an original diagnostic tumor tissue or the most recent metastatic tumor biopsies (archival biopsy or de novo biopsy) and a peripheral blood sample for Notch receptors genomic profiling
Exclusion
- Known brain metastases.
- Prior treatment with gamma secretase inhibitor or other Notch signaling inhibitor.
Key Trial Info
Start Date :
February 3 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 14 2016
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT02299635
Start Date
February 3 2015
End Date
January 14 2016
Last Update
January 8 2019
Active Locations (37)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford Cancer Institute
Stanford, California, United States, 94305
2
Stanford Hospital and Clinics
Stanford, California, United States, 94305
3
Stanford Women's Cancer Center
Stanford, California, United States, 94305
4
The University of Chicago Medical Center
Chicago, Illinois, United States, 60637